Equity Profile

SUPN

Supernus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.7B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative therapies for neurological and psychiatric disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.51

Revenue

Revenue reflects the company's sales performance and market demand for its products, which is crucial for growth.

$205M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative therapies for neurological and psychiatric disorders. With a market cap of $3 billion, it plays a significant role in the pharmaceuticals sector, particularly in addressing unmet medical needs in mental health.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1-2026, Supernus reported an EPS of -$0.04, missing expectations significantly. The stock reacted positively, gaining 1.15% the next day despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Supernus to report a modest recovery in Q2-2026, with a consensus EPS of $0.51 and revenue of $205 million. The market is watching closely for any signs of improved performance after recent misses.

Bull Case

If Supernus can exceed the EPS and revenue estimates, it may signal a turnaround in its financial performance, boosting investor confidence.

Bear Case

Conversely, another earnings miss could further erode trust in management's ability to deliver on promises, leading to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.51

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$205M

Revenue reflects the company's sales performance and market demand for its products, which is crucial for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Supernus achieve an EPS of at least $0.51?

This figure is crucial for restoring investor confidence after recent earnings misses.

What factors contributed to the revenue target of $205 million?

Understanding the drivers behind revenue expectations will help gauge the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Supernus to rebound, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

The company has a history of surprising the market with new product performance.

Options pricing suggests traders are anticipating a larger move than historical averages.

Recent insider activity may indicate confidence in upcoming product launches.

Key Risk

If revenue comes in significantly above $207 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of earnings misses, and the market is looking for signs of improvement.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.44 would solidify the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests the stock could rise by about 1.1%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 1.83%, as the market reacts negatively to ongoing performance issues.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on cost management strategies and their effects on margins.
3Insights into market demand for current and upcoming therapies.
4Management's outlook on competitive pressures in the pharmaceuticals sector.
5Details on any strategic partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative therapies for neurological and psychiatric disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.51

Revenue

Revenue reflects the company's sales performance and market demand for its products, which is crucial for growth.

$205M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1-2026, Supernus reported an EPS of -$0.04, missing expectations significantly. The stock reacted positively, gaining 1.15% the next day despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Supernus can exceed the EPS and revenue estimates, it may signal a turnaround in its financial performance, boosting investor confidence.

Bear Case

Conversely, another earnings miss could further erode trust in management's ability to deliver on promises, leading to a decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.51

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$205M

Revenue reflects the company's sales performance and market demand for its products, which is crucial for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Supernus achieve an EPS of at least $0.51?

This figure is crucial for restoring investor confidence after recent earnings misses.

What factors contributed to the revenue target of $205 million?

Understanding the drivers behind revenue expectations will help gauge the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Supernus to rebound, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

The company has a history of surprising the market with new product performance.

Options pricing suggests traders are anticipating a larger move than historical averages.

Recent insider activity may indicate confidence in upcoming product launches.

Key Risk

If revenue comes in significantly above $207 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of earnings misses, and the market is looking for signs of improvement.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating a strong recovery.

Bear Confirmed If

An EPS below $0.44 would solidify the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests the stock could rise by about 1.1%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline of around 1.83%, as the market reacts negatively to ongoing performance issues.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on cost management strategies and their effects on margins.
3Insights into market demand for current and upcoming therapies.
4Management's outlook on competitive pressures in the pharmaceuticals sector.
5Details on any strategic partnerships or collaborations that could enhance growth.